Seagen Inc

NASDAQ:SGEN  
136.88
+1.18 (+0.87%)
Products

Seagen Announces Tukysa In Combination With Trastuzumab Granted Priority Review By FDA For Previously Treated HER2-Positive Metastatic Colorectal Cancer

Published: 09/19/2022 12:31 GMT
Seagen Inc (SGEN) - Seagen Announces Tukysa® (tucatinib) in Combination With Trastuzumab Granted Priority Review by FDA for Previously Treated Her2-positive Metastatic Colorectal Cancer.
Seagen Announces Tukysa® (tucatinib) in Combination With Trastuzumab Granted Priority Review by FDA for Previously Treated Her2-positive Metastatic Colorectal Cancer.
Seagen Inc - FDA Has Set Action Date of January 19, 2023.